Why your joints wear out, and what we are trying to do about it.
Osteoarthritis is the world's most common joint disease and one of its most stubborn, partly because cartilage, once gone, doesn't really grow back. A tour of what's happening inside an aching joint, and where the new generation of treatments fits in.
A patient walks into a clinic with knee pain. She is sixty-two. The pain came on slowly, over years, the way most chronic things do, first a little ache after long walks, then mornings of stiffness, then nights where the joint throbs in time with her pulse. She has tried glucosamine, ibuprofen, a knee brace from a friend. Now she is sitting on the exam table asking the question every orthopaedic surgeon hears, in some form, every working day.
What is actually happening inside my knee?
Here is the honest answer.
What a joint really is
A joint is, structurally, a remarkable piece of engineering. Two bones meet and slide against each other inside a sealed capsule. The ends of those bones are capped with cartilage, a glassy, almost translucent tissue, mostly water held inside a scaffold of collagen. Between the cartilage surfaces is a thin film of synovial fluid, which is itself extraordinary: under low pressure it is slippery, and under high pressure it stiffens, so the joint glides under weight without grinding.
This whole system is fed and cleaned by something most patients have never heard of: a network of tiny vessels in the surrounding tissue, half of them carrying blood, the other half carrying lymph. The lymphatic vessels are the joint’s drainage system. They pull excess fluid, dead cells, and inflammatory debris out of the joint capsule and ferry it back into circulation, where the immune system can deal with it.
When everything works, you don’t think about any of this. The whole apparatus is, in healthy young adults, almost frictionless.
What goes wrong
Osteoarthritis, OA, is what we call this whole system breaking down. For decades it was taught as a wear-and-tear disease: the cartilage gets used up, like the tread on a tyre, and once it’s gone, it’s gone. That picture is half right. Cartilage really does not regenerate the way bone does. But the reason it doesn’t is more interesting than mechanical wear.
Inside an osteoarthritic joint, the immune system is involved earlier and more deeply than we used to think. Cartilage cells, chondrocytes, start producing inflammatory signals. Macrophages, the immune system’s clean-up crew, arrive in the synovial lining. Small chemokines pull in more immune cells. The joint becomes, quietly, a low-grade inflammatory environment.
Changes in lymphatic vessels may also be part of the process, although their precise role in human osteoarthritis is still being established.
This question is where some of my recent work has focused. In a 2026 review with colleagues in Bone Research, we surveyed evidence on lymphatic biology in musculoskeletal disease. Experimental and observational studies suggest that lymphatic structure and function can change during joint disease. Whether that change is a cause, a consequence, or both in human osteoarthritis remains uncertain.
It is a useful research hypothesis that extends the older wear-and-tear model, not yet a settled explanation for every patient.
Why most treatments don’t fix it
Once inflammation and possible drainage changes are considered together, several research questions become easier to frame.
Anti-inflammatory medicines can reduce pain for some people with OA, but benefit and risk vary. They have not been shown to restore lost cartilage, and they require individual assessment because topical and oral preparations have different risks.
Hyaluronic acid injections remain controversial: recommendations differ across guidelines, and evidence does not support presenting them as cartilage-restoring treatment.
Corticosteroid injections may provide short-term symptom relief in selected situations. Questions remain about repeated use, so benefits, alternatives and risks should be discussed for the individual patient.
Joint replacement can substantially improve pain and function for appropriately selected patients, but it is major surgery with limitations and risks. Many people need a useful, adaptable non-operative plan long before replacement is appropriate.
That gap, between an over-the-counter painkiller and a major operation, is where the next generation of treatments is being built.
What’s coming
The active research in joint disease today is, broadly, trying to do three things at once: calm inflammation locally, restore drainage, and create conditions where what’s left of the cartilage can heal. A few of the most promising directions:
Immunomodulatory injectables. Instead of generic anti-inflammatories that suppress the whole immune system, drugs that nudge specific immune cells, particularly macrophages, from their inflammatory state into a repair state. The biology is well understood; the delivery is the hard part. You need the drug to stay in the joint long enough to work, without leaking everywhere else.
Hydrogels. Injectable biomaterials are being studied as scaffolds and local drug-delivery systems. Their composition, residence time, biological effects and clinical readiness vary widely; experimental promise should not be mistaken for routine treatment.
Lymphatic-directed therapy. This is newer and more speculative, but follows directly from the drainage-failure idea: drugs or interventions that promote lymphatic vessel growth or function inside the joint. Most of the published work is still preclinical, but the rationale is strong.
Senolytic and metabolic approaches. Old chondrocytes, like old cells everywhere, sometimes fail to die properly and instead sit around producing inflammatory signals. Drugs that selectively clear those cells, senolytics, are being trialled across multiple age-related diseases, including OA.
None of these approaches should be described as routine disease-modifying care. Development timelines are uncertain, and success in laboratory or animal studies does not guarantee clinical benefit.
What this means for the patient on the exam table
For a person living with knee OA now, guidelines place education and tailored therapeutic exercise at the centre of care, with weight-management support when relevant. Medicines, injections and surgery require individual assessment, shared decisions and review rather than a universal treatment ladder.
Research is active, but it would be misleading to promise when a disease-modifying treatment will become available or who will benefit.
That is the part of this work that keeps me at the bench. Not the elegant immunology or the clever materials. The fact that, somewhere down the line, the patient with the throbbing knee gets a different answer than the one we have been giving for a hundred years.
The underlying review on lymphatic biology in musculoskeletal disease is open access at Bone Research. This essay is an editorial draft and should not be used as personal medical advice.